Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS

Date

2021-09-09

Authors

Shetty, Ashok K.
Shetty, Padmashri A.
Zanirati, Gabriele
Jin, Kunlin

ORCID

0000-0002-1336-348X (Jin, Kunlin)

Journal Title

Journal ISSN

Volume Title

Publisher

Springer Nature

Abstract

Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional phase II/III trials are required to validate the efficacy of MSCs to improve the survival of COVID-19 patients with ARDS. Future studies also need to assess the efficacy of MSCs to prevent long COVID.

Description

Keywords

Citation

Shetty, A. K., Shetty, P. A., Zanirati, G., & Jin, K. (2021). Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS. NPJ Regenerative medicine, 6(1), 53. https://doi.org/10.1038/s41536-021-00161-z

Rights

© The Author(s) 2021.

License

Attribution 4.0 International (CC BY 4.0)